Optimizing the Value of Medical Imaging in Oncology Clinical Trials

Medical imaging is increasingly playing a valuable role as a means for surrogate endpoints in clinical research, particularly within oncology development programs. As primary efficacy measures for oncology are normally long term endpoints, the effectiveness of a new therapy may be assessed by quantifying the size and number of tumors visualized by imaging examinations. This provides insights into drug efficacy much faster than relying on traditional clinical endpoints such as patient survival, which may be contaminated by subsequent alternative therapies or additional medications. Use of imaging as a surrogate endpoint can therefore be a valuable means of demonstrating unmet clinical needs and ultimately accelerating approval of a new drug.

Please submit the required fields in the form below to obtain your complimentary copy of the Optimizing the Value of Medical Imaging in Oncology Clinical Trials white paper. You will receive your copy of the white paper instantly after submission.